![Láser CO2 asociado a rapamicina tópica: una estrategia terapéutica en los angiofibromas faciales | Piel. Formación continuada en dermatología Láser CO2 asociado a rapamicina tópica: una estrategia terapéutica en los angiofibromas faciales | Piel. Formación continuada en dermatología](https://multimedia.elsevier.es/PublicationsMultimediaV1/file//02139251/0000003700000009/v1_202210290602/S0213925122000624/v1_202210290602/es/main.assets/gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNcZKUBDXoOvgE2vzRlJsQjLfRxZftokmIrvlsS6Vnj6EVfzlSctkGu3bmIskNJi+X5rIiUvwQZOESFdSdh3gQN+P65GXiUNcEoGbxf0Gznt5QoNW2Df+lRlNa1gxe8k+1xjsbEmr4ZHyh6hiwGwhiaeYsfrqZ1UVDC4f0zyHZoTzIdMpEgom45qHrjvBvC07e7h5aSmiRjsfgCcEXMABBqaUguAnhQcMsX4rOjGWemCYg==)
Láser CO2 asociado a rapamicina tópica: una estrategia terapéutica en los angiofibromas faciales | Piel. Formación continuada en dermatología
Farmacia Dr. Ternelli - Pronti unguenti a base di Sirolimus (Rapamicina) per Sclerosi Tuberosa. #sirolimus #rapamicina #sclerosituberosa #angiofibromifacciali #dermatology #dermatologia #crema #farmacia #pharmacy #laboratorio #lab #laboratoriogalenico ...
![Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma - Indian Journal of Dermatology, Venereology and Leprology Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma - Indian Journal of Dermatology, Venereology and Leprology](https://ijdvl.com/content/126/2015/81/5/Images/ijdvl_2015_81_5_540_163800_u1.jpg)
Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma - Indian Journal of Dermatology, Venereology and Leprology
![Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex: A Randomized Clinical Trial | Semantic Scholar Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex: A Randomized Clinical Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/63ab7bdd014faad450bc752dda72fdce3bf8d3b4/7-Figure4-1.png)
Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex: A Randomized Clinical Trial | Semantic Scholar
![Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial | Trials | Full Text Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial | Trials | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13063-019-3767-8/MediaObjects/13063_2019_3767_Fig1_HTML.png)